Solomon Kibret Birhanie
I’m specialized in vectorborne diseases surveillance, ecology and control. I use spatial and temporal mosquito data to understand the ecology of mosquitoborne diseases. Using field, remote-sensing and laboratory data, I look into factors associated with vectorborne diseases transmission. I have developed some tools to help predict mosquito population around permanent water bodies such as reservoirs and irrigation schemes. Some of my research findings have been widely disseminated through streamline media such as CNN, Reuters, Washington Post and SciDev.Net
CNN: https://www.cnn.com/2015/09/11/africa/africa-malaria-dams/index.html
Reuters: https://www.reuters.com/article/us-africa-malaria-dams-idUSKCN11B02Y
Reuters: https://www.reuters.com/article/africa-malaria-dams-idINKCN0RB1RU20150911
Washington Post: https://www.washingtonpost.com/news/energy-environment/wp/2015/09/11/malaria-cases-in-africa-are-soaring-heres-the-surprising-reason-why/
The Conversation: https://theconversation.com/dams-increase-the-risk-of-malaria-heres-why-123475
ScieDev.Net: https://www.scidev.net/sub-saharan-africa/news/african-dams-linked-one-million-malaria-cases-year/
CNN: https://www.cnn.com/2015/09/11/africa/africa-malaria-dams/index.html
Reuters: https://www.reuters.com/article/us-africa-malaria-dams-idUSKCN11B02Y
Reuters: https://www.reuters.com/article/africa-malaria-dams-idINKCN0RB1RU20150911
Washington Post: https://www.washingtonpost.com/news/energy-environment/wp/2015/09/11/malaria-cases-in-africa-are-soaring-heres-the-surprising-reason-why/
The Conversation: https://theconversation.com/dams-increase-the-risk-of-malaria-heres-why-123475
ScieDev.Net: https://www.scidev.net/sub-saharan-africa/news/african-dams-linked-one-million-malaria-cases-year/
less
Related Authors
InterestsView All (9)
Uploads
Papers by Solomon Kibret Birhanie
Methods: An observational cohort study was conducted with patients treated for uncomplicated P. falciparum malaria with either single-dose PQ (0.25 mg/kg) (SLD PQ) + ACT or ACT alone. Microscopy-confirmed uncomplicated P. falciparum malaria patients visiting public health facilities in Arjo Didessa, Southwest Ethiopia, were enrolled in the study from September 2019 to November 2022. Patients with uncomplicated P. falciparum malaria were followed up for 28 days through clinical and laboratory diagnosis, such as measurements of G6PD levels and haemoglobin (Hb) concentrations. G6PD levels were measured by a quantiative CareSTART ™ POCT S1 biosensor machine. Patient interviews were also conducted, and the type and frequency of clinical complaints were recorded. Hb data were taken on days (D) 7, 14, 21, and 28 following treatment with SLD-PQ + ACT or ACT alone. Results A total of 249 patients with uncomplicated P. falciparum malaria were enrolled in this study. Of these, 83 (33.3%) patients received ACT alone, and 166 (66.7%) received ACT combined with SLD-PQ treatment. The median age of the patients was 20 (IQR 28-15) years. G6PD deficiency was found in 17 (6.8%) patients, 14 males and 3 females. There were 6 (7.2%) and 11 (6.6%) phenotypic G6PD-deficient patients in the ACT alone and ACT + SLD-PQ arms, respectively. The mean Hb levels in patients treated with ACT + SLD-PQ were reduced by an average of 0.45 g/dl (95% CI = 0.39 to 0.52) in the posttreatment phase (D7) compared to a reduction of 0.30 g/dl (95% CI = 0.14 to − 0.47) in patients treated with ACT alone (P = 0.157). A greater mean Hb reduction was observed on day 7 in the G6PDd ACT + SLD-PQ group (− 0.60 g/dL) than in the G6PDd ACT alone group (− 0.48 g/dL)
water management.
Methods: An observational cohort study was conducted with patients treated for uncomplicated P. falciparum malaria with either single-dose PQ (0.25 mg/kg) (SLD PQ) + ACT or ACT alone. Microscopy-confirmed uncomplicated P. falciparum malaria patients visiting public health facilities in Arjo Didessa, Southwest Ethiopia, were enrolled in the study from September 2019 to November 2022. Patients with uncomplicated P. falciparum malaria were followed up for 28 days through clinical and laboratory diagnosis, such as measurements of G6PD levels and haemoglobin (Hb) concentrations. G6PD levels were measured by a quantiative CareSTART ™ POCT S1 biosensor machine. Patient interviews were also conducted, and the type and frequency of clinical complaints were recorded. Hb data were taken on days (D) 7, 14, 21, and 28 following treatment with SLD-PQ + ACT or ACT alone. Results A total of 249 patients with uncomplicated P. falciparum malaria were enrolled in this study. Of these, 83 (33.3%) patients received ACT alone, and 166 (66.7%) received ACT combined with SLD-PQ treatment. The median age of the patients was 20 (IQR 28-15) years. G6PD deficiency was found in 17 (6.8%) patients, 14 males and 3 females. There were 6 (7.2%) and 11 (6.6%) phenotypic G6PD-deficient patients in the ACT alone and ACT + SLD-PQ arms, respectively. The mean Hb levels in patients treated with ACT + SLD-PQ were reduced by an average of 0.45 g/dl (95% CI = 0.39 to 0.52) in the posttreatment phase (D7) compared to a reduction of 0.30 g/dl (95% CI = 0.14 to − 0.47) in patients treated with ACT alone (P = 0.157). A greater mean Hb reduction was observed on day 7 in the G6PDd ACT + SLD-PQ group (− 0.60 g/dL) than in the G6PDd ACT alone group (− 0.48 g/dL)
water management.